Yasuhiro Matsumura

This inventor holds 10 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: National Cancer Center, Rin Institute Inc., Nanocarrier Co., Ltd.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasuhiro Matsumura. Retrieved from https://idiyas.com/inventor/yasuhiro-matsumura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 90.0

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 11(Granted Patents)

Location History:

Kashiwa, JP (2016 - 2021)
Tokyo, JP (2019 - 2022)
Chiba, JP (2022 - 2023)

Company Filing History:

10 out of 264

National Cancer Center

Nanocarrier Co., Ltd.

The University of Tokyo

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600797 - FIBRIN-BINDING ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY (2026-04-14),

2. 12509507 - FUSION PROTEIN SUITABLE FOR DISSOLVING FIBRIN CLOT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID FUSION PROTEIN (2025-12-30),

3. 11633499 - Anti-TMEM-180 antibody, anticancer drug and cancer testing method (2023-04-25),

4. 11524074 - Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method (2022-12-13),

5. 11377504 - Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same (2022-07-05),

6. 11311626 - Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate (2022-04-26),

7. 11192956 - Antibody binding to TMEM132A, anticancer agent, and cancer test method (2021-12-07),

8. 10471146 - Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method (2019-11-12),

9. 9920133 - Anti-tissue factor monoclonal antibody (2018-03-20),

10. 9429584 - Antibody against insoluble fibrin (2016-08-30),

Title: Yasuhiro Matsumura: Pioneering Innovations in Cancer Treatment

Introduction

Yasuhiro Matsumura, a prominent inventor based in Chiba, Japan, has made significant contributions to the field of cancer research. With a total of 8 patents to his name, Matsumura is recognized for his groundbreaking work in developing innovative anticancer drugs and testing methods that target specific molecules associated with cancer cells.

Latest Patents

Among his latest inventions, the most notable include his work on the Anti-TMEM-180 antibody, which aims to create an effective anticancer drug. This invention focuses on identifying target molecules specifically expressed in cancer cells, allowing for targeted actions that could effectively treat cancer. Furthermore, the patent also presents a cancer testing method that involves measuring the levels of TMEM-180 in samples collected from subjects. His commitment to advancing cancer treatment is further reflected in his development of a cancer-cell-specific anti-TMEM-180 monoclonal antibody and associated anticancer strategies.

Career Highlights

Matsumura has had a notable career, collaborating with reputable organizations like Rin Institute Inc. and the National Cancer Center. His research and inventions have played a crucial role in advancing cancer therapies, showcasing his dedication to improving patient outcomes.

Collaborations

Throughout his career, Matsumura has worked alongside distinguished colleagues such as Masahiro Yasunaga and Shingo Hanaoka. These collaborations have not only enhanced his research capabilities but also contributed to the collective effort in cancer innovation, emphasizing the importance of teamwork in scientific advancement.

Conclusion

Yasuhiro Matsumura continues to be a significant figure in the realm of cancer treatment innovation. His patents reflect a commitment to discovering targeted therapies and more effective testing methods, showcasing the role of inventors like him in shaping the future of medicine and providing hope to patients battling cancer.

Profile summary based on public USPTO records.